Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
IRVINE, Calif., Feb. 18, 2016 -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2015 financial results, which will take place on Monday, February 22, 2016 after the close of the market.
Endologix will hold a conference call on Monday, February 22, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.endologix.com.
After the live webcast, a replay of the webcast will remain available online from the investor relations page of Endologix's website, www.endologix.com, through February 22, 2017. In addition, a transcript will be posted to the website and a telephonic replay of the call will be available until February 29, 2016. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay pin number 13629814.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
ENDOLOGIX CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020
